Media Spotlight | Making a Strong Start in the 15th Five-Year Plan: Jiangxi Integrates Bio-Industry Innovation to Build an “Accelerator” for Biopharmaceutical Innovation

Preface:

2026 year 2 month 14 On [date], the national-level Jinggangshan Economic Development Zone issued the “…” “ The 15th Five-Year Plan ” Making a Strong Start | Jiangxi Bio: Integrating Production and Innovation to Drive Biopharmaceutical Breakthroughs “ Accelerator ” », reporting that Jiangxi Bio is “ Pilot-Scale Platform for Biological Immune Antibody Drugs ” Innovation drives research outcomes from “ From Laboratory to Industrialization ” the key conversion performance. This platform was 2025 year 12 month 3 Selected for the Jiangxi Provincial Department of Industry and Information Technology’s… 2025 “List of Pilot-Scale Platforms for Manufacturing in Jiangxi Province for the Year,” thereby becoming the province’s first pilot-scale platform for bioimmunological antibody drugs.

Leveraging substantial capital investment and a state-of-the-art equipment infrastructure, the Jiangxi Biologics Pilot-Scale Platform for Biological Immunomodulatory Antibody Drugs has established end-to-end, modular pilot-scale capabilities that comprehensively upgrade key process steps. By innovatively replicating real-world manufacturing conditions, the platform accelerates the translation of early-stage research findings into clinical-grade drug candidates that meet regulatory submission requirements. As a result, the overall R&D cycle is expected to be further shortened, while the efficiency and robustness of technology transfer are poised to improve.

Figure: “Notice of the Jiangxi Provincial Department of Industry and Information Technology on the Publication of” 2025 Notice on the List of Pilot Platforms for Manufacturing in Jiangxi Province for the Year

Source: National-level Jinggangshan Economic Development Zone

What kind of innovative sparks will fly when an entrepreneur’s market insight meets a scientist’s meticulous R&D craftsmanship in the laboratory? At Jiangxi Institute of Biological Products Co., Ltd. (hereinafter referred to as “ Jiangxi Biology ” ), this kind of “ produce ” and “ research ” This encounter is giving rise to a development in the biopharmaceutical field. “ Innovation Revolution ” By establishing the province’s first pilot-scale platform for bioimmunological antibody drugs, they have enabled research findings to bridge the gap between the laboratory and the production line. “ Valley of Death ” , elevating the efficiency of technology transfer to a new high.

“ Innovative Expressway ” the precision engine on it

In the science and technology innovation chain, the pilot-scale testing stage is referred to as “ From 1 to 100 inches the critical leap that stands between the laboratory and real-world applications, often proving insurmountable for many science-and-tech startups “ Valley of Death ” . Jiangxi Bio relies on a total investment of nearly 3000 The province’s first pilot-scale platform for bioimmunological antibody drugs, built with an investment of 10,000 yuan, is striving to turn this “ valley ” Turn into “ bridge ” , to enable research achievements to transcend “ The Last Mile ” Provide strong support.

The pilot-scale platform currently occupies approximately 600 square meters, with plans to expand to in the future 800 square meters, equipped with 86 A total of [number] sets of high-end instruments and equipment, with a combined value exceeding RMB 10 million. The platform focuses on the field of bioimmunological antibody drugs and has established a comprehensive system spanning from... “ Antigen Development and Detection — Immune antibody plasma — Refined enzymatic digestion and purification — Formulation filling — Analysis and Testing ” A full-chain, modular pilot-scale system capable of advancing early-stage target discovery to mature candidates that meet the regulatory requirements for clinical trial application.

“ Here, we can simulate the actual production environment and bring the laboratory’s ‘ Spark of Inspiration ’ Convert into a mature sample qualified for clinical submission. ” According to the head of the Jiangxi Bio-Platform, this innovative model is expected to shorten the R&D cycle by nearly, on average. 40% , the success rate of research-to-application translation has been elevated to an industry-leading level.

of industry-innovation integration “ Innovation Alliance ”

In practice, pilot-scale platforms are not only for technology validation “ Touchstone ” , and even more so in overcoming tough challenges “ Sharp tool ” Leveraging its deep technical expertise, the Jiangxi biotechnology research team has repeatedly demonstrated its value in major national projects and in addressing critical industry challenges: it successfully developed the national standard reference material for tetanus antitoxin, which has been officially recognized by national authoritative bodies; it pioneered a new analytical method to tackle the longstanding challenge of testing human equine immune serum products, thereby removing significant technical barriers for the industry; and it has even helped overseas partner companies resolve issues related to low product purity. “ Chokehold ” The challenge is to rapidly produce three batches of high-quality stock solutions, demonstrating both robust research capabilities and efficient alignment with industry needs.

Layouting future tracks “ Innovation Incubator ”

In the face of the global wave of biopharmaceutical innovation, Jiangxi Bio is at a critical stage of upgrading the quality of its antiserum products and advancing cutting-edge technologies; it is currently the only company worldwide that uses recombinant proteins, mRNA and companies developing serum-free antigens. The company has proactively positioned itself in the next-generation technology pipeline, developing cutting-edge purification technologies such as caprylic acid purification, ion-exchange chromatography, and specific affinity chromatography, while exploring formulations that also function as adjuvants. mRNA Antigen synthetic biology and LNP Applications in cutting-edge fields such as lipid delivery systems, immobilized specific recombinase-mediated cleavage technology, human-derived organoids and organ-on-a-chip evaluation platforms, and bispecific antibodies, while integrating digital twin technology to create “ Visible, Optimizable, Predictable ” an intelligent R&D system.

Meanwhile, through “ Leading Talent Recruitment Program ” In collaboration with schools and enterprises, the platform is currently fostering a vibrant ecosystem. “ Innovative Rainforest ” Here, not only can technological achievements be rapidly commercialized, but innovative talent can also receive comprehensive support, enabling “ Innovation Seeds ” to “ Industrial Giant ” a magnificent transformation.

In the tide of innovation-driven development, Jiangxi Bio has, through the construction of a pilot-scale testing platform, not only facilitated the commercialization of scientific and technological achievements, “ The Ren and Du Meridians ” , and has further pioneered a path of biopharmaceutical innovation with Chinese characteristics, and in 2025 Within one year, obtain two clinical trial approvals for new drugs from the National Medical Products Administration and one TAT Vial packaging NMPA Production approval number. This platform is rapidly emerging as a hub for biopharmaceutical innovation that radiates throughout the city and exerts influence across the entire province, continuously injecting technological momentum into the building of a Healthy China.

-  The end -

Regarding Jiangxi Institute of Biological Products Co., Ltd.

Jiangxi Institute of Biological Products Co., Ltd. is the leading enterprise in China’s antiserum industry and a national high-tech enterprise, with its history dating back to 1969 The Jiangxi Branch of the Shanghai Institute of Biological Products, established by the Ministry of Health in [year], is one of the few global companies that have achieved full-industry-chain integration in the antiserum sector. Adhering to the mission of “providing high-quality medicines for people worldwide,” the company focuses on four core therapeutic areas—viral infections, bacterial and bacterial-toxin infections, biotoxin poisoning, and autoimmune diseases—to build a world-class hub for antiserum products. To date, its products have been exported to markets around the globe. 30 In numerous countries and regions, we have provided services to over one billion patients worldwide, continuously contributing China’s strength to global public health. For more information, please visit: https://www.jxswzp.cn/ 。